NASDAQ:XERS Xeris Biopharma (XERS) Stock Price, News & Analysis $6.84 +0.24 (+3.64%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$6.82 -0.02 (-0.29%) As of 08/8/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Xeris Biopharma Stock (NASDAQ:XERS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Xeris Biopharma alerts:Sign Up Key Stats Today's Range$6.54▼$6.9350-Day Range$4.35▼$6.8452-Week Range$2.21▼$7.09Volume11.44 million shsAverage Volume2.36 million shsMarket Capitalization$1.07 billionP/E RatioN/ADividend YieldN/APrice Target$6.25Consensus RatingModerate Buy Company Overview Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Read More Xeris Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreXERS MarketRank™: Xeris Biopharma scored higher than 60% of companies evaluated by MarketBeat, and ranked 382nd out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingModerate Buy Consensus RatingXeris Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageXeris Biopharma has received no research coverage in the past 90 days.Read more about Xeris Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Xeris Biopharma are expected to grow in the coming year, from ($0.41) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xeris Biopharma is -32.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xeris Biopharma is -32.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.50% of the outstanding shares of Xeris Biopharma have been sold short.Short Interest Ratio / Days to CoverXeris Biopharma has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Xeris Biopharma has recently increased by 164.55%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXeris Biopharma does not currently pay a dividend.Dividend GrowthXeris Biopharma does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.57 Percentage of Shares Shorted12.50% of the outstanding shares of Xeris Biopharma have been sold short.Short Interest Ratio / Days to CoverXeris Biopharma has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Xeris Biopharma has recently increased by 164.55%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News Sentiment0.85 News SentimentXeris Biopharma has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Xeris Biopharma this week, compared to 3 articles on an average week.Search Interest19 people have searched for XERS on MarketBeat in the last 30 days. This is an increase of 58% compared to the previous 30 days.MarketBeat Follows3 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Xeris Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $109,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.47% of the stock of Xeris Biopharma is held by insiders.Percentage Held by Institutions42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xeris Biopharma's insider trading history. Receive XERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address XERS Stock News HeadlinesXeris Biopharma (NASDAQ:XERS) Hits New 12-Month High After Earnings Beat2 hours ago | americanbankingnews.comXeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call TranscriptAugust 7 at 8:04 PM | seekingalpha.comThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.” | Weiss Ratings (Ad)Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue GuidanceAugust 7 at 7:21 AM | finance.yahoo.comXeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025July 31, 2025 | businesswire.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a favorite amongst institutional investors who own 54%July 31, 2025 | finance.yahoo.comXeris Biopharma Holdings, Inc. (XERS) - Yahoo FinanceJuly 10, 2025 | finance.yahoo.comXeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term InvestingJune 18, 2025 | seekingalpha.comSee More Headlines XERS Stock Analysis - Frequently Asked Questions How have XERS shares performed this year? Xeris Biopharma's stock was trading at $3.39 at the beginning of the year. Since then, XERS stock has increased by 101.8% and is now trading at $6.84. How were Xeris Biopharma's earnings last quarter? Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) issued its earnings results on Thursday, August, 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The firm had revenue of $67.71 million for the quarter, compared to analysts' expectations of $64.58 million. Read the conference call transcript. When did Xeris Biopharma IPO? Xeris Biopharma (XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager. Who are Xeris Biopharma's major shareholders? Top institutional shareholders of Xeris Biopharma include Geode Capital Management LLC (2.33%), Connor Clark & Lunn Investment Management Ltd. (0.79%), Y Intercept Hong Kong Ltd (0.21%) and Diversified Trust Co (0.11%). Insiders that own company stock include Paul R Edick, Kevin Mcculloch, John Patrick Shannon Jr and Beth Hecht. View institutional ownership trends. How do I buy shares of Xeris Biopharma? Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xeris Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xeris Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CymaBay Therapeutics (CBAY) and CrowdStrike (CRWD). Company Calendar Last Earnings8/07/2025Today8/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XERS CIK1867096 Webwww.xerispharma.com Phone(844) 445-5704FaxN/AEmployees290Year FoundedN/APrice Target and Rating Average Price Target for Xeris Biopharma$6.25 High Price Target$8.00 Low Price Target$4.00 Potential Upside/Downside-8.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$54.84 million Net Margins-13.01% Pretax Margin-21.41% Return on EquityN/A Return on Assets-8.10% Debt Debt-to-Equity RatioN/A Current Ratio1.72 Quick Ratio1.17 Sales & Book Value Annual Sales$203.07 million Price / Sales5.27 Cash FlowN/A Price / Cash FlowN/A Book Value($0.20) per share Price / Book-34.20Miscellaneous Outstanding Shares156,380,000Free Float146,267,000Market Cap$1.07 billion OptionableOptionable Beta0.65 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:XERS) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.